166 related articles for article (PubMed ID: 31084773)
1. Evolving Role of PET-Based Novel Quantitative Techniques in the Management of Hematological Malignancies.
Raynor WY; Zadeh MZ; Kothekar E; Yellanki DP; Alavi A
PET Clin; 2019 Jul; 14(3):331-340. PubMed ID: 31084773
[TBL] [Abstract][Full Text] [Related]
2. Critical role of PET/CT-based novel quantitative techniques for assessing global disease activity in multiple myeloma and other hematological malignancies: why it is time to abandon reliance on examining focal lesions.
Taghvaei R; Zadeh MZ; Werner TJ; Alavi A
Eur Radiol; 2021 Jan; 31(1):149-151. PubMed ID: 33125560
[No Abstract] [Full Text] [Related]
3. Clinical Application of
Zirakchian Zadeh M
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):800-814. PubMed ID: 37558532
[TBL] [Abstract][Full Text] [Related]
4. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
5. Personalized Management Approaches in Lymphoma: Utility of Fluorodeoxyglucose-PET Imaging.
Ayers EC; Fardin S; Gholami S; Alavi A; Mato AR
PET Clin; 2016 Jul; 11(3):209-18. PubMed ID: 27321026
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
[TBL] [Abstract][Full Text] [Related]
7. PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma.
Kostakoglu L; Chauvie S
PET Clin; 2019 Jul; 14(3):317-329. PubMed ID: 31084772
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET imaging in hematological malignancies.
Valls L; Badve C; Avril S; Herrmann K; Faulhaber P; O'Donnell J; Avril N
Blood Rev; 2016 Jul; 30(4):317-31. PubMed ID: 27090170
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of therapy for lymphoma.
Jerusalem G; Hustinx R; Beguin Y; Fillet G
Semin Nucl Med; 2005 Jul; 35(3):186-96. PubMed ID: 16098292
[TBL] [Abstract][Full Text] [Related]
10. MRI and PET/MRI in hematologic malignancies.
Mayerhoefer ME; Archibald SJ; Messiou C; Staudenherz A; Berzaczy D; Schöder H
J Magn Reson Imaging; 2020 May; 51(5):1325-1335. PubMed ID: 31260155
[TBL] [Abstract][Full Text] [Related]
11. PET Imaging for Hematologic Malignancies.
Hughes NM; Jacene HA
Radiol Clin North Am; 2021 Sep; 59(5):705-723. PubMed ID: 34392914
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
14. The role of
Ayubcha C; Hosoya H; Seraj SM; Zadeh MZ; Werner T; Alavi A
Hell J Nucl Med; 2019; 22(1):4-5. PubMed ID: 30843002
[TBL] [Abstract][Full Text] [Related]
15. When should FDG-PET be used in the modern management of lymphoma?
Barrington SF; Mikhaeel NG
Br J Haematol; 2014 Feb; 164(3):315-28. PubMed ID: 24131306
[TBL] [Abstract][Full Text] [Related]
16. PET imaging for response assessment in lymphoma: potential and limitations.
Schöder H; Moskowitz C
Radiol Clin North Am; 2008 Mar; 46(2):225-41, viii. PubMed ID: 18619378
[TBL] [Abstract][Full Text] [Related]
17. The role of FDG PET in the management of lymphoma: what is the evidence base?
Kirby AM; Mikhaeel NG
Nucl Med Commun; 2007 May; 28(5):335-54. PubMed ID: 17414883
[TBL] [Abstract][Full Text] [Related]
18. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
19. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
20. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
